Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative

Maass, L.; Verho, M; Rangoonwala, R.; Malerczyk, V.; Hajdú, P; Klesel, N

doi:10.1007/bf01646053

Cited by 21 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous investigators [10–13] have also involved various microbiological assay methods, including both microdilution and agar dilution, to quantitate cefpirome. Two studies [13, 14] reported the pharmacokinetics of cefpirome in adults after quantitation of the compound in serum by using high-performance liquid chromatography (HPLC) assay for which specific details were not provided.…”

Section: Introductionmentioning

confidence: 99%

New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk and Pharmaceutical Dosage Forms

Rao

Kumar²,

Joydeep³

2011

Sci. Pharm.

View full text Add to dashboard Cite

A simple stability indicating reversed-phase HPLC method was developed and subsequently validated for estimation of Cefpirome sulphate (CPS) present in pharmaceutical dosage forms. The proposed RP-HPLC method utilizes a LiChroCART-Lichrosphere100, C18 RP column (250 mm × 4mm × 5 μm) in an isocratic separation mode with mobile phase consisting of methanol and water in the proportion of 50:50 % (v/v), at a flow rate 1ml/min, and the effluent was monitored at 270 nm. The retention time of CPS was 2.733 min and its formulation was exposed to acidic, alkaline, photolytic, thermal and oxidative stress conditions, and the stressed samples were analyzed by the proposed method. The described method was linear over a range of 0.5–200μg/ml. The percentage recovery was 99.46. F-test and t-test at 95% confidence level were used to check the intermediate precision data obtained under different experimental setups; the calculated value was found to be less than the critical value.

show abstract

Section: Introductionmentioning

confidence: 99%

New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk and Pharmaceutical Dosage Forms

Rao

Kumar²,

Joydeep³

2011

Sci. Pharm.

View full text Add to dashboard Cite

show abstract

Single‐ and Multiple‐Dose Pharmacokinetics of Intravenous Cefpirome (HR810) to Healthy Volunteers

Nakayama

Akieda²,

Yamaji

et al. 1992

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The safety and pharmacokinetics of single and multiple administrations of cefpirome (HR810), a new cephalosporin antibiotic agent with a broad antibacterial spectrum, were studied in healthy male volunteers. The single administration protocols included a 3-minute intravenous injection of 0.5 g or 1 g, and a 1-hour intravenous drip infusion of 0.5 g, 1 g, or 2 g. The multiple administration protocols included nine intravenous injections and 1-hour intravenous drip infusions of 1 g of cefpirome twice a day at intervals of 12 hours. Cefpirome was tolerated, and only a few mild, subjective and hepatic-function side effects were observed. There were no severe abnormalities. The drug concentrations in the plasma and the urine were determined by means of HPLC and bioassay, and the results correlated well (r = 0.99). The pharmacokinetic parameters were calculated using a two-compartment model. The elimination half-life (t1/2 beta) was about 1.7 hours for both intravenous injection and intravenous drip infusion and was not dose-dependent. AUC and Cmax were dose-dependent in this study, although an accumulation due to multiple administrations was not observed, and there were no changes in the pharmacokinetic parameters after the initial and the final administrations. The recovery rate of the unchanged compound in the urine was more than 80% in the 24 hours after a single administration and was the same after multiple administrations. Bioautography did not show any active metabolites in the plasma or the urine. The results, for safety and pharmacokinetics, show that cefpirome can be expected to have excellent clinical efficacy for bacterial infections.

show abstract

Determination of cefpirome (HR 810) in serum and urine

1988

View full text Add to dashboard Cite

Cefpirome (HR 810) is a new cephalosporin under clinical investigation. Specific and sensitive HPLC- and agar-diffusion methods were developed for the determination of serum- and urine concentrations. The methods are fully validated according to the IFCC Recommendations on Quality Control in Clinical Chemistry. In order to demonstrate the usefulness of both methods, pharmacokinetic profiles of cefpirome after 1 g i.v. administration to human volunteers are presented.

show abstract

Single and multiple dose pharmacokinetics of intravenous cefpirome (HR 810), a novel cephalosporin derivative

Cited by 21 publications

References 4 publications

New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk and Pharmaceutical Dosage Forms

New Stability Indicating RP-HPLC Method for the Estimation of Cefpirome Sulphate in Bulk and Pharmaceutical Dosage Forms

Single‐ and Multiple‐Dose Pharmacokinetics of Intravenous Cefpirome (HR810) to Healthy Volunteers

Determination of cefpirome (HR 810) in serum and urine

Contact Info

Product

Resources

About